GEN Exclusives

More »

GEN News Highlights

More »
Mar 16, 2010

Pfizer to Assess Tekmira Technology to Deliver siRNAs in Preclinical Models

  • Tekmira and Pfizer will collaborate on evaluating Tekmira's stable nucleic acid-lipid particle (SNALP) technology to deliver siRNA molecules provided by Pfizer. Tekmira will be responsible for preparing the SNALP formulations, and Pfizer will evaluate the formulations in preclinical models.

    SNALP technology encapsulates siRNAs in uniform lipid nanoparticles, which are effective in delivering RNAi therapeutics to disease sites in preclinical models, according to Tekmira. SNALP formulations are manufactured by a proprietary method that is robust, scalable, and highly reproducible, the firm adds.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?